BioSpace News Archive

Aran Biomedical, a trusted partner in the design, development and manufacture of implantable medical devices is pleased to announce the appointment of Mr. Todd Blair as Vice President of Sales and Business Development (US), with effect 1 st July 2020 . This role has been created to meet and manage the growing demand for Aran Bi

Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced the publication of an original paper in the Journal of Clinical Psychopharmacology that describes a model that may facilitate dosage optimization of JORNAY PM® (methylphenidate

Therap is happy to announce the addition of the Secure Communications (SComm) on its mobile applications platform for iOS and Android devices

Respected Vision Industry Veteran to Accelerate Success for Leader in Color Vision Solutions

The Company Tendered One Time Cash Payment to Odyssey Capital LLC to Fully Repay This Debenture (“Note”) There Will be No Conversions or Share Issuances in Connection With This Debt Retirement NEW YORK, NY, June 29, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemo

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera’s drug development facility in Solna, Sweden . The agreement is an important step in the development of Oncopeptides’ pre-clinical operations and marks an additional reinforcement of the Company’s research capacity

Scientists have new evidence that overactive neutrophils—a common type of circulating immune cell—may drive the life-threatening blood clots and inflammation that occur in some patients with COVID-19.

Today, the U.S. Food and Drug Administration approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer. P

Medline announced a $120 million annual partnership with The University of Texas System Supply Chain Alliance.

Ten finalists have been named in the prestigious annual “Make Your Medical Device Pitch for Kids!” competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI).